EHA 2009

 
 
 

The 14th Congress of the European Society of Hematology took place June 4-7, 2009, in Berlin, Germany.

 

New drug appears safe and active in MF

Jen Smith Read Article
Published: 06/19/09

Ayalew Tefferi, MD
Ayalew Tefferi, MD

A phase 1 study suggests TG101348 is well tolerated and has considerable activity in myelofibrosis, a finding that echoes results observed in preclinical research of the drug. Ayalew Tefferi, MD, of the Mayo Clinic, and his colleagues tested TG101348 in patients with primary myelofibrosis or myelofibrosis occurring after polycythemia vera or essential thrombocythemia. He presented preliminary results at the 14th Congress of the European Hematology Association. [Read Article]

Study suggests azacitidine reverts disease

HT Staff Read Article
Published: 06/18/09

Sylvain Thépot
Sylvain Thépot

New research suggests azacitidine can revert disease in patients who present with myeloproliferative neoplasms (MPNs) and later develop myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Sylvain Thépot, of Hôpital Avicenne, and his colleagues analyzed the effects of azacitidine in MPN patients who developed MDS or AML. In addition to promising responses, the researchers saw a reappearance of MPN features following azacitidine treatment. [Read Article]

Long-term therapy improves HRQOL in ITP

Jen Smith Read Article
Published: 06/17/09

James Bussel, MD
James Bussel, MD

Results of two studies suggest eltrombopag improves health-related quality of life (HRQOL) in patients with immune thrombocytopenic purpura (ITP). In the RAISE and EXTEND studies, patients receiving eltrombopag experienced an increase in platelet counts and a reduction in bleeding symptoms. And these factors may account for the improvement in HRQOL, according to a presentation at the 14th Congress of the European Hematology Association. [Read Article]

Lestaurtinib falls short in myelofibrosis

Jen Smith Read Article
Published: 06/16/09

Fabio P.S. Santos, MD
Fabio P.S. Santos, MD

Lestaurtinib demonstrates only minor benefits in patients with difficult-to-treat, JAK2V617F-positive myelofibrosis, according to a phase 2 study. The drug did reduce spleen size in some patients, but because it also increased toxicity, patients did not experience an improvement in quality of life. In addition, lestaurtinib had no effect on JAK2 allele burden or bone marrow fibrosis. Fabio P.S. Santos, MD, presented this data at the 14th Congress of the European Hematology Association. [Read Article]

Speaker advocates allo-SCT in elderly ALL

HT Staff Read Article
Published: 06/15/09

Bone marrow aspirate showing ALL
Bone marrow aspirate
showing ALL

Allogeneic stem cell transplant (SCT) should be more widely used to treat elderly patients with acute lymphocytic leukemia (ALL), said a presenter at the 14th Congress of the European Hematology Association. Renate Arnold, MD, of Charité University Medicine Berlin, and her colleagues observed a survival rate of 52% in elderly ALL patients who underwent allogeneic SCT, which is significantly better than the survival rate in patients who receive chemotherapy. [Read Article]

Everolimus shrinks lymphoma tumors

Mark Fuerst Read Article
Published: 06/14/09

The mTOR inhibitor everolimus significantly reduces tumor size by 50% or more in one third of patients with refractory or relapsed lymphomas. Up to 60% of patients with aggressive types of non-Hodgkin’s lymphoma (NHL), including the most common NHL, diffuse large B-cell lymphoma (DLBCL), may be cured with appropriate therapy. However, NHL patients have a high risk of relapse after initial therapy, and no treatments are currently available to reduce this risk. [Read Article]

Study reveals new benefits of intrabone CBT

Jen Smith Read Article
Published: 06/12/09

Francesco Frassoni, MD
Francesco Frassoni, MD

Previous research has suggested that intrabone administration can improve engraftment in cord blood transplant, but new research indicates this route offers other benefits over intravenous infusion. A presentation at the 14th Congress of the European Hematology Association showed that intrabone administration not only improved neutrophil and platelet recovery, but it lowered the rate of graft-versus-host disease and improved overall survival. [Read Article]

Romiplostim better than standard therapies in ITP

Jen Smith Read Article
Published: 06/11/09

Mathias Rummel, MD, PhD
Mathias Rummel, MD, PhD

Romiplostim is superior to standard therapies for previously treated, nonsplenectomized patients with chronic immune thrombocytopenic purpura, a new study suggests. Romiplostim reduced the need for splenectomy and the incidence of treatment failure. And although the drug resulted in a slightly higher incidence of adverse events, these proved transient. Mathias Rummel, MD, PhD, presented this study at the 14th Congress of the European Hematology Association. [Read Article]

Docs debate leukemogenesis of hydroxyurea

Jen Smith Read Article
Published: 06/10/09

Magnus Bjorkholm, MD, PhD
Magnus Bjorkholm, MD, PhD

Hydroxyurea may not be as leukemogenic as researchers have come to believe. In fact, a speaker at the 14th Congress of the European Hematology Association said the drug may not cause leukemia at all. Magnus Bjorkholm, MD, PhD, showed that, in patients with myeloproliferative neoplasms, hydroxyurea did not cause myelodysplastic syndrome or acute myeloid leukemia. However, the validity of this finding was a point of contention in the discussion following his presentation. [Read Article]

Researchers find a way to target KRAS

Jen Smith Read Article
Published: 06/09/09

Stefan Fröhling, MD
Stefan Fröhling, MD

Activating KRAS mutations have long seemed impossible targets for therapy, but researchers have now discovered a way to target these oncogenes. Stefan Fröhling, MD, and his colleagues found the STK33 gene plays a key role in the activity of cells dependent on mutant KRAS. And suppressing STK33 inhibits the viability and proliferation of these cells. Dr Fröhling presented these findings at the 14th Congress of the European Hematology Association. [Read Article]

Germans suggest new standard therapy for HL

HT Staff Read Article
Published: 06/08/09

Andreas Engert, MD
Andreas Engert, MD

German investigators say they have found a new standard of care for patients with early unfavorable Hodgkin’s lymphoma. A regimen of 2 courses of escalated BEACOPP, 2 courses of ABVD, and involved-field radiation, proved more effective than the current standard of therapy in this patient population—4 courses of ABVD and involved-field radiation. Andreas Engert, MD, presented this finding at the 14th Congress of the European Hematology Association. [Read Article]

T-cell drug effective in B-cell lymphomas

HT Staff Read Article
Published: 06/07/09

Follicular lymphoma cells
Follicular lymphoma cells

A drug typically used in T-cell lymphoma demonstrates single-agent activity in B-cell lymphomas, according to data presented at the 14th Congress of the European Hematology Association. A phase 2 study showed that vorinostat, which is currently approved for the treatment of cutaneous T-cell lymphoma, elicits considerable responses in heavily pretreated patients with relapsed or refractory follicular lymphoma or marginal zone B-cell lymphoma. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}